TG THERAPEUTICS, INC.: 10-Q filed 2017-11-09
What TG THERAPEUTICS, INC. reported in its quarterly report filed 2017-11-09 (fiscal Q3 2017): 21 published measures, 56 facts as tagged in accession 0001654954-17-010322.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-11-09
- Fiscal period
- fiscal Q3 2017
- Accession
- 0001654954-17-010322 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TG THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 101,781,514 | USD | |
| At 2016-12-31 | 54,781,547 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 22,235,748 | USD | |
| At 2016-12-31 | 18,913,745 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 91,842,167 | USD | |
| At 2016-12-31 | 25,031,280 | USD | |
| At 2016-09-30 | 29,156,521 | USD | |
| At 2015-12-31 | 55,061,329 | USD |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 2,227 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 323,015 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | -324,003,065 | USD | |
| At 2016-12-31 | -236,386,820 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 268,366 | USD | |
| At 2016-12-31 | 328,148 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 12,375,306 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 6,181,400 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -31,585,227 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -87,677,020 | USD | 273 |
| 2016-07-01 to 2016-09-30 | -24,925,471 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -54,941,070 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 97,661,296 | USD | |
| At 2016-12-31 | 50,864,144 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 19,789,614 | USD | |
| At 2016-12-31 | 16,878,440 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 799,391 | USD | |
| At 2016-12-31 | 799,391 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 31,623,323 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 87,791,306 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 24,963,567 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 55,055,356 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 27,149,050 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 76,536,742 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 21,797,756 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 46,948,827 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 70,652,267 | shares | |
| At 2016-12-31 | 56,779,113 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 403,712,474 | USD | |
| At 2016-12-31 | 272,432,139 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 79,545,766 | USD | |
| At 2016-12-31 | 35,867,802 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 0 | USD | |
| At 2016-12-31 | 164,375 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -31,535,652 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -87,616,245 | USD | 273 |
| 2016-07-01 to 2016-09-30 | -24,831,027 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -54,578,751 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 4,474,273 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 11,254,564 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 3,165,811 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 8,106,529 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 62,009 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 42,464 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 49,575 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 60,775 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 94,444 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 362,319 | USD | 274 |
Inspect the source
- Entity
- TG THERAPEUTICS, INC. / CIK 0001001316
- Captured
- SEC response SHA-256
153d276440c1903144d2ca193676af4b7014428a3e4b5524efe33528427880b3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001001316.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))